Venous thromboembolism, a frequent and severe disease, has clinically important early and late complications and a strong tendency to recur. Anticoagulant therapy is the mainstay of treatment, performed by immediate administration of: i) parenteral anticoagulants followed by vitamin K antagonists, either dabigatran or edoxaban, two direct oral anticoagulants (DOACs); or ii) direct rivaroxaban or apixaban, two DOACs that can be used as single-drug approach. Treatment should last no less than 3 months in all patients though how long it should last thereafter is a more complex issue. The risk of recurrence results from several event-or patient-associated factors. Some patients have low risk and may be treated for 3 to 6 months only. Others (the majority) have a high risk of recurrence (approximately 50% in 10 years). Unfortunately, the protective effect of anticoagulation against recurrence is present only during treatment and is lost when therapy is stopped. For this reason, international guidelines recommend that there is no pre-definite period of anticoagulation (e.g. 1 or 2 years, and so on) in patients at high risk and suggest instead indefinite (extended) anticoagulation, provided there is no high risk of bleeding. When the decision is difficult, adjunctive criteria may be adopted, such as male sex and abnormal D-dimer assessed after anticoagulation is stopped, to identify patients at high risk who need indefinite therapy. The use of DOACs, especially at lower doses with a lower risk of bleeding, may make indefinite anticoagulation for patients easier.
Introduction
Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) of lower limbs and/or pulmonary embolism (PE), is a severe, potentially lethal disease. Its incidence is high, affecting 1 to 2 out of 1000 persons per year in developed countries, [1] [2] [3] and represents the third most common cardiovascular disease, after myocardial infarction and stroke. 4 VTE is an acute disease that may have clinically important outcomes early and late after initial presentation. All patients with acute VTE need immediate active anticoagulant therapy. This treatment may require administration of: i) parenteral drugs (heparin or derivatives) followed by vitamin K antagonists (VKAs) or by the direct oral anticoagulants (DOACs) dabigatran and edoxaban; 5, 6 or ii) oral administration of the DOACs apixaban or rivaroxaban, drugs that may be used as a first-alone drug in the first days of treatment and in the following months, at the appropriate dosages. 7, 8 VTE may also have late, clinically important consequences. Post-thrombotic syndrome (PTS), a condition that greatly affects the morbidity and quality of life of patients and is associated with high social costs, is a late outcome of DVT. PTS, particularly frequent after recurrent DVT in the same leg of the first event, was detected in mild, moderate or severe form in 30%, 10% and 3% of patients, respectively, two years after first DVT. 9 Another important late complication is chronic thromboembolic pulmonary hypertension, detected in as many as 3.8% of patients two years after an acute episode of PE. N o n -c o m m e r c i a l u s e o n l y acute phase; this is true when either VKAs 11 or DOACs [5] [6] [7] [8] are used. VTE has, however, a strong tendency to recur. Though recurrent VTE episodes or extension of the disease may occur in some patients even in the presence of adequate therapy (≈4% after a DVT), 12, 13 the risk of recurrence increases sharply after anticoagulation is stopped. This is why some authors claim VTE is a chronic disease. 14 Clinical studies have investigated the effects of different anticoagulant treatment times in subjects after VTE event, and found that three-month treatment gives better results than a shorter period and achieves a similar risk of recurrence after anticoagulation cessation as a longer course of treatment. 15 Furthermore, it was shown that whatever the duration of the anticoagulant treatment, its benefit faded after anticoagulation was stopped and the risk of recurrence increased again. [16] [17] [18] [19] Based on these results, the recent American College of Chest Physician (ACCP) guidelines recommend that all patients with acute VTE should receive no less than 3 months of anticoagulation, a period considered necessary to cover the initial and maintenance phases of VTE. A longer but definite time-period of anticoagulation (e.g. 1 year, 2 years, etc.) is not recommended, since the risk of recurrence increases again after therapy is stopped. 20 The mentioned guidelines suggest, therefore, that patients at high risk of recurrent VTE and non-high risk of bleeding should be evaluated for indefinite anticoagulant treatment, i.e. no pre-established limited duration of treatment, with periodical clinical control of patient's conditions.
The clinical risk associated with recurrent venous thromboembolism and risk factors for recurrences
The patients' clinical conditions significantly worsen after recurrent events. A recurrent DVT in the same leg strongly increases the risk of developing postthrombotic syndrome [heart rate 6.4; confidence interval (CI) 3.1-13.3] and it is associated with a reduction in survival. 21, 22 Recurrent PE is the strongest risk factor for chronic pulmonary hypertension 23 with the risk of recurrence falling over time after the first VTE. A recent systematic review found a 0.4% (CI 0.3-0.6) rate of fatal recurrent VTE, with a case-fatality rate of 11.3% (CI 8.0-15.2) during the first 3 months of anticoagulant therapy; after the first 3 months the rate of fatal recurrence was 0.3% patient-years (CI 0.1-0.4), with a case fatality rate reduced to 3.6% (CI 1.9-5.7). 24 The risk factors for VTE recurrence may be related State of the art with an expert to the nature and type of the index event, and to the characteristics of the patient (Table 1) . Patients whose VTE occurred without any strong VTE risk factor (unprovoked VTE) benefit from extended anticoagulation therapy, whereas those with VTE associated with a triggering and removed major risk factor do not. Furthermore, a recent study showed that some patients with VTE associated to minor persistent or transient risk factors may also benefit from extended anticoagulation therapy.
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Timing and criteria to decide the duration of anticoagulation in individual venous thromboembolism patients
When to tackle the decision
Some clinical conditions which clearly point to short or extended anticoagulation may be present at the moment of VTE diagnosis; the treating clinicians can therefore inform the patients about the expected duration of anticoagulant therapy at the moment of diagnosis. In most cases, however, the issue of anticoagulation duration is assessed only after 3 to 6 months of treatment. Many factors may affect the risk of recurrent VTE events and more risk factors can be present in a single patient. Each patient should, therefore, be evaluated paying attention to all possible influencing factors and also to his/her preference ( Table 2) .
Candidates for a short anticoagulation period
Candidates for a short anticoagulation period (usually lasting 3 to 6 months) are the following: 21 presence of homozygous or double heterozygous factor V Leiden and prothrombin G20210A mutations, 33, 34 and antiphospholipid syndrome. 35 In contrast, the presence of the very frequent heterozygous factor V Leiden or prothrombin G20210A mutations do not seem to justify indefinite anticoagulation. -Patients whose index event was a PE presenting with shock or life-threatening prolonged hypotension. This is justified by studies reporting that patients presenting with PE are more likely to suffer from a new PE by way of recurrence than patients presenting with DVT, thus exposing them to higher clinical risk. 26, 36 In a retrospective study, 37 VTE recurrence was in 70% of cases a new PE episode in patients presenting with PE, but only 15% in patients with DVT. Furthermore, the increased clinical risk associated with recurrent PE episodes was demonstrated by Douketis et al. 38 who found a higher rate of recurrent fatal PE in patients with a first VTE presenting as PE than in those with DVT (1.2% vs 0.3%, respectively).
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Patients whose venous thromboembolism was associated with non-surgical risk factors (probably associated with increased risk)
Several VTE-associated risk factors have been identified and discussed 39 though clinical research is still needed to conclude whether or not their presence needs extended anticoagulation. Currently their presence/absence is not sufficient to decide the duration of anticoagulation in single patients: -The persistence of residual vein thrombosis (RVT) in DVT-involved deep veins of lower limbs was found to be associated with the risk of recurrent DVT in some [40] [41] [42] [43] though not all studies. [44] [45] [46] Two randomized studies showed that persistent RVT was a good criterion for determining the duration of anticoagulation. 47, 48 A recent systematic review concluded that after a first unprovoked DVT, RVT is a weak overall predictor of recurrent VTE, with a stronger association if RVT is detected early after thrombosis. 49 In the DULCIS study (D-dimer and ULtrasonography in Combination Italian Study) 50 patients with RVT at screening received one year of anticoagulation and after this period no difference was recorded in the rates of recurrent events in relation to the presence/absence of RVT in patients who stopped anticoagulation. -Men are exposed to higher risk than females. 51, 52 A recent study showed that men had a 2.2-fold higher risk of recurrent events than women, a difference that was present only after an unprovoked VTE and disappeared when the first event was provoked. 53 -The effect of increasing age on the risk of recurrence is still uncertain, since an increased risk has been detected only in some, 22, 32, 54 though not all studies. [55] [56] [57] -Being overweight and obese were found to be associated with a higher risk of recurrence.
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-Increased levels of some blood clotting factors were associated with the risk of a first and also of recurrent VTE; this was shown for factor VIII 59, 60 and factor IX.
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-Some inherited thrombophilic alterations, such as the heterozygous presence of factor V Leiden or of prothrombin G20210A mutations, highly frequent in general Caucasian population, are risk factors for VTE but do not confer a higher risk of recurrence. 62, 63 A meta-analysis of prospective studies demonstrated only a slightly increased risk of recurrent VTE in patients who had a heterozygous FV factor V Leiden (relative risk 1.4, 95% CI 1.1-1.8) or prothrombin G20210A mutation (relative risk 1.7, 95% CI 1.3-2.3). 64 In these patients, accurate antithrombotic prophylaxis in all conditions associated with increased thrombotic risk seems to be adequate. -Recent guidelines 65 indicate that long distance travel (usually considered at least 4 h) is also a weak risk factor, with a risk that is higher in individuals with pre-existing risk factors for VTE.
-Patients with inflammatory bowel disease had a higher risk of recurrence according to a recent study. 66 In conclusion, while the possible presence of these factors should be assessed, their presence in most cases is not enough to decide between short or extended anticoagulation.
Absence of triggering factors (unprovoked events)
Between 25% and 50% of all patients with first VTE had the event in the absence of major risk factors (so called unprovoked, or idiopathic events). 7, 67, 68 In general, this category of patients is considered at high risk of recurrence and the recent AT 10 ACCP guidelines suggest giving extended anticoagulation to all subjects, provided they are not at high risk of bleeding. 20 However, a better risk-stratification among this large group of unprovoked patients seems appropriate and has also been recommended. 69 In this regard, the above-mentioned guidelines suggest treating physicians take into account other characteristics (such as male sex and abnormal D-dimer levels) in case of doubt about the duration of treatment. 
The role of D-dimer testing to assess individual risk of venous thromboembolism (VTE) recurrence in unprovoked VTE patients
Plasma D-dimer levels are considered an indirect marker of coagulation activation. Besides the well-established use of D-dimer assay for the diagnostic procedure in symptomatic outpatients with suspected acute VTE, the test has also been proposed to assess individual risk of recurrent VTE. A prospective, inception-cohort study, for the first time showed a significantly higher hazard ratio for recurrence in subjects with abnormal versus normal D-dimer at 3 months (2.45; 95% CI 1.28-4.53; P<0.01). 70 Similar results were subsequently obtained. 71, 72 In a multicenter, prospective, randomized study (PROLONG study), patients with abnormal D-dimer, measured one month after warfarin was stopped, were randomly assigned to either stop or resume VKAs while those with negative D-dimer did not resume anticoagulation. 73 During 18 months follow-up, the incidence of recurrent VTE was 6.2% (4.4%/y) in those with normal Ddimer test but 2.9% (2.0%/y) and 15.0% (10.9%/y) in patients with abnormal D-dimer randomized to resume or not anticoagulation. That study demonstrated that patients with abnormal D-dimer 1 month after anticoagulation is withdrawn, have a high risk of recurrence and deserve extended anticoagulation. The predictive value for VTE recurrence has been confirmed by one systematic review, 74 one metaanalysis, 75 and a patient-level meta-analysis. 76 In the more recent, multicenter, prospective DUL-CIS study 50 unprovoked patients underwent serial Ddimer assessment, starting during VKA treatment and several times after discontinuation. Patients with a positive D-dimer result (measured using the local routine assay and adopting specific cut-off values) (42.3% of total 1010 patients), were recommended to continue or resume VKA anticoagulation (the only available at that time), whereas those with persistently negative results stopped anticoagulation definitively. At 18 months follow-up, primary outcomes occurred in 3.0%/y of patients with negative D-dimer, and in 8.8%/y (hazard ratio 2.92, 95% CI 1.87-9.72; P=0.0006) in patients who had positive D-dimer results but refused to resume anticoagulation. The 373 patients, who resumed anticoagulation for positive Ddimer, had very few recurrences though they did have an unacceptably high incidence of major bleeding (2.3%/y).
A higher VTE recurrence rate in patients who stopped anticoagulation for negative D-dimer testing (assessed with a qualitative assay) was recorded in a subsequent study. 77 As discussed more in detail elsewhere, 78 it needs to be borne in mind that the rate of positive D-dimer results in the Kearon study was much lower than expected on the basis of comparable studies, probably due to the use of an insufficiently sensitive assay. A low rate of abnormal D-dimer results translates into more false-negative results.
Algorithms to predict the risk of venous thromboembolism recurrence
Several clinical decision rules (CDR) have been proposed to help stratify patients with unprovoked VTE for the risk of recurrence so as to be able to inform the decision about duration of anticoagulation; all CDR include D-dimer measurement.
In 2008 Rodger et al. 57 proposed, and recently validated, 79 a CDR called: Men continue and HERDOO2. According to this CDR, long-term anticoagulant treatment is always indicated for all males; while women at low risk of recurrence and who may discontinue anticoagulation are those who, after 5-7 months of oral anticoagulant therapy, have 0 or only 1 of the following features: i) post-thrombotic signs (hyperpigmentation, edema or redness in either leg); ii) D-dimer level ≥250 μg/L (measured during anticoagulation); iii) body mass index ≥30 kg/m 2 ; iv) age ≥65 years. Eichinger et al. 80 proposed a nomogram that includes the following three variables, significantly associated with recurrence: i) sex (male>female); ii) location of index VTE event (PE>proximal DVT>dis-tal DVT); and iii) elevated levels of D-dimer measured after anticoagulation was stopped. The nomogram has recently been validated in different patients. 81 Tosetto et al. elaborated 82 and validated 83 a prognostic recurrence score called DASH, that includes: i) abnormal D-dimer (2 points); ii) age <50 years (1 point); iii) sex (male 1 point); and iv) index event in women that was associated with hormonal therapy (-2 points). On the basis of this CDR, patients with 0 or 1 score are at low risk of recurrence and can avoid lifelong anticoagulation.
The risk of bleeding during anticoagulation
The duration of anticoagulation after VTE should balance the risk of recurrence and that of bleeding. Many factors may influence the risk of bleeding during VKA treatment, 84 with complications in patients who start VKA anticoagulation for the first time significantly higher during the first 3 months of treatment than thereafter. 85 A meta-analysis of available studies found a 2%/y risk of major bleeding during the first 3 months, and a 2.7%/y in the subsequent period. 86 Though higher rates of bleeding can be expected in real-life treatment, phase III clinical trials on DOACs showed low rates of major bleeds (from 0.6%/y to 1.2%/y) in DOAC-treated patients, whereas in comparator-treated subjects (usually low-molecularweight heparin + warfarin) the rates ranged between 1.2%/y and 2.2%/y. 20 It is, however, not easy to assess the individual risk of bleeding in VTE patients. The above guidelines propose a categorization of bleeding risk in anticoagulated patients on the basis of the presence of the following risk factors: age >65 years, age >75 years, previous bleeding, cancer, metastatic cancer, renal or liver failure, diabetes, previous stroke, anemia, thrombocytopenia, presence of comorbidities, antiplatelet therapy, nonsteroidal anti-inflammatory drugs, poor anticoagulant control, recent surgery, frequent falls, alcohol abuse. The risk of bleeding during anticoagulation with VKA is low in patients without risk factors, moderate in those with 1 factor, and high in those with ≥2 factors. 20 Other bleeding risk scores have also been proposed; it should be noticed, however, that they all have only a modest predictive value for patients with VTE. 88 In conclusion, it is not easy to predict the individual risk of bleeding in VTE patients, who are generally much younger than patients treated for atrial fibrillation and usually do not have a personal history of bleeding events.
The duration of treatment in the era of direct oral anticoagulants and of other antithrombotic drugs
The DULCIS study showed that the resumption and extension of anticoagulation with VKA in patients with abnormal D-dimer was associated with a high incidence of major bleeding complications (2.3%/y). 50 Phase III trials 89 and recent real-life studies have shown that DOAC use in VTE patients is in general associated with a low rate of bleeding. It seems, therefore, reasonable to propose their use instead of VKAs for extended anticoagulation. Two randomized clinical trials have focused on the use of low-dose DOACs for extended therapy in VTE patients. A low dose of apixaban (2.5 mg BID) was found to be equally effective against recurrences than the standard treatment dose (5 mg BID), with a very low rate of bleeding. 90 Recently, a prophylactic dose of rivaroxaban (10 mg OID) proved to be as effective as the standard treatment dose (20 mg OID), and more effective than aspirin (100 mg/day), without increasing the risk of bleeding complications. 91 In contrast with previous studies, [92] [93] [94] these results seem to deny any advantage of using low dose aspirin for extended treatment after a VTE versus DOACs. It can be concluded that low dose apixaban or rivaroxaban may be a good opportunity for extended treatment, and that aspirin would not be a good choice, especially if we bear in mind its not negligible bleeding risk, particularly in elderly patients. 95 In line with the results of the mentioned trials on DOAC use for extended treatment, a new clinical study has been designed and is currently running: the APIDULCIS study (coordinators: Palareti G. and Prandoni P.) is an Italian, prospective, multicenter cohort study, that includes patients aged 75 years or younger, who are candidates for extended anticoagulant treatment because of a first VTE event that was unprovoked or associated with a weak risk factor. All these patients would be candidates for indefinite anticoagulation according to the ACCP guidelines; however, after completing 12 months of anticoagulant therapy (whatever the drug used), serial D-dimer testing is performed to try to distinguish subjects at low risk of recurrence (with D-dimer persistently negative) in whom extended anticoagulation can be avoided, from those (with an abnormal D-dimer result) who are at increased risk of recurrence and deserve extended anticoagulation through administration of apixaban 2.5 mg BID for 18 months. The drug is courteously provided by Alliance BMS-Pfizer.
The effect of sulodexide administration, a glycosaminoglycan with antithrombotic and profibrinolytic actions and low bleeding risk when administered orally, has recently been investigated in a placebo-controlled, double-blind trial for prevention of recurrent VTE after a standard course of anticoagulant treatment. 96 The patients who received sulodexide had a 50% reduction of recurrences versus those receiving placebo (P=0.02), without any occurrence of major bleeding episodes. These results are promising, especially for a potentially safe and effective protection in patients with high risk of bleeding if treated with anticoagulants (e.g. elderly patients).
Practical suggestions on decision about anticoagulant duration after a venous thromboembolism event
As shown in Table 2 , a decision is easy to take for patients who have characteristics clearly justifying short or, vice-versa, indefinite anticoagulation. However, this is not true for many patients, especially those with unprovoked events, who can roughly be estimated to represent approximately half of all new VTE patients. Since the risk of bleeding does not seem to be high or is uncertain in the majority of these patients, o n l y most of them are candidates for indefinite anticoagulant treatment; however, we know that only 50% of them are expected to have a recurrence in 10 years without anticoagulation. 22 The decision to opt for indefinite anticoagulation in all these patients is not easy. This is also recognized by the ACCP guidelines that, for a better selection of patients for extended VTE therapy, suggest including two additional criteria: patient sex (males are at higher risk of recurrence than females and abnormal D-dimer levels 1 month after anticoagulation is stopped). The ACCP guidelines also recommend involving the patients and considering their preference for the final decision. 20 As practical guidance, the following procedure may be suggested to decide on duration of anticoagulant therapy after VTE: -All patients with VTE should receive 3 to 6 months of initial anticoagulation and be re-considered after that period to assess risk of recurrence if anticoagulation is stopped and bleeding if anticoagulation is extended. -Patients at high risk of bleeding (according to the ACCP score 20 or other criteria) are informed about this risk and -in general -are advised to stop anticoagulation; all elderly patients (>75 years old) are in this condition. -All patients with leg DVT should receive compression ultrasonography (CUS) of proximal deep veins when stopping anticoagulation in order to have a baseline result in case of subsequent suspected ipsilateral recurrence. In patients with nonhigh risk of bleeding and RVT (>4 mm at CUS) a longer anticoagulation course, e.g. 6 to 12 months, may be advisable after which the persistence of RVT does not seem to have any effect on recurrence rates. 49, 50 -Anticoagulation should be stopped after the initial period (3 to 6 months) in patients with provoked events (associated with trigger -and removedfactors). -Patients at high risk of recurrence are advised to undergo extended anticoagulation for an indefinite time (with periodical checks to assess the balance between benefit and risks). -Patients with an unprovoked event or associated with weak risk factors are candidates for indefinite anticoagulation, provided they are not at high risk of bleeding. They should be informed about future recurrence risk if anticoagulation is stopped and told that international guidelines recommend an indefinite anticoagulation for this condition. However, they can also be informed about the fact that an alternative management procedure is possible, 50 based on use of serial D-dimer testing to assess individual risk of recurrence, and identify patients who, having a high risk (with abnormal D-dimer levels after anticoagulation is withdrawn), deserve extended anticoagulation. On the contrary, patients with persistently negative D-dimer results are informed about their risk of recurrence is low enough not to extend anticoagulation. -Any final decision should be taken in accordance with patient preference; after accurate and complete information is given, they may prefer extending anticoagulation for greater protection or stopping due to potential risks.
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